LANCET HIV - Lancet HIV
Publikationen
- 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Turkova, A., Waalewijn, H., Chan, M. K., Bollen, P. D. J., Bwakura-Dangarembizi, M. F., Kekitiinwa, A. R., Cotton, M. F., Lugemwa, A., Variava, E., Ahimbisibwe, G. M., Srirompotong, U., Mumbiro, V., Amuge, P., Zuidewind, P., Ali, S. S., Kityo, C. M., Archary, M., Ferrand, R. A., Violari, A., Gibb, D. M., Burger, D., Ford, D., Colbers, A. & ODYSSEY Trial Team, 09.2022, in: LANCET HIV. 9, 9, S. E627-E637Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
Amuge, P., Lugemwa, A., Wynne, B., Mujuru, H. A., Violari, A., Kityo, C. M., Archary, M., Variava, E., White, E., Turner, R. M., Shakeshaft, C., Ali, S., Nathoo, K. J., Atwine, L., Liberty, A., Bbuye, D., Kaudha, E., Mngqibisa, R., Mosala, M., Mumbiro, V., Nanduudu, A., Ankunda, R., Maseko, L., Kekitiinwa, A. R., Giaquinto, C., Rojo, P., Gibb, D. M., Turkova, A., Ford, D. & ODYSSEY Trial Team, 09.2022, in: LANCET HIV. 9, 9, S. e638-e648Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung